These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1518 related articles for article (PubMed ID: 28404761)

  • 21. Non-Small Cell Lung Cancer, Version 6.2015.
    Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Dilling TJ; Dobelbower MC; Govindan R; Grannis FW; Horn L; Jahan TM; Komaki R; Krug LM; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Rohren E; Schild SE; Shapiro TA; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M;
    J Natl Compr Canc Netw; 2015 May; 13(5):515-24. PubMed ID: 25964637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
    Aredo JV; Padda SK
    Curr Treat Options Oncol; 2018 Jun; 19(8):43. PubMed ID: 29951788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive markers in the adjuvant therapy of non-small cell lung cancer.
    Filipits M; Pirker R
    Lung Cancer; 2011 Dec; 74(3):355-63. PubMed ID: 21885151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
    Uprety D
    Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
    [No Abstract]   [Full Text] [Related]  

  • 25. Non-small cell lung cancer.
    Ettinger DS; Akerley W; Borghaei H; Chang AC; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Ganti AK; Govindan R; Grannis FW; Horn L; Jahan TM; Jahanzeb M; Kessinger A; Komaki R; Kong FM; Kris MG; Krug LM; Lennes IT; Loo BW; Martins R; O'Malley J; Osarogiagbon RU; Otterson GA; Patel JD; Pinder-Schenck MC; Pisters KM; Reckamp K; Riely GJ; Rohren E; Swanson SJ; Wood DE; Yang SC; Hughes M; Gregory KM;
    J Natl Compr Canc Netw; 2012 Oct; 10(10):1236-71. PubMed ID: 23054877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
    Ko EC; Raben D; Formenti SC
    Clin Cancer Res; 2018 Dec; 24(23):5792-5806. PubMed ID: 29945993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
    Reck M
    Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
    Osmani L; Askin F; Gabrielson E; Li QK
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Career in Lung Cancer: Pushing Beyond Chemotherapy.
    Patil PD; Shepherd F; Johnson DH
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():583-589. PubMed ID: 31099660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region.
    Jazieh AR; Bamefleh H; Demirkazik A; Gaafar RM; Geara FB; Javaid M; Khader J; Khodadad K; Omar W; Saadeddin A; Sabe HA; Shadmehr MB; El Sherif A; Uddin N; Jahanzeb M; Ettinger D;
    J Natl Compr Canc Netw; 2010 Jul; 8 Suppl 3():S16-21. PubMed ID: 20697125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
    D'Argento E; Rossi S; Schinzari G; Strippoli A; Basso M; Cassano A; Barone C
    Curr Treat Options Oncol; 2016 Dec; 17(12):59. PubMed ID: 27766545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [35th Congress of the American Society of Clinical Oncology, Atlanta, USA, 15-18 May 1999. Non-small-cell lung tumors].
    Foggi P
    Clin Ter; 1999; 150(3):181-6. PubMed ID: 10528429
    [No Abstract]   [Full Text] [Related]  

  • 33. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
    Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
    Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
    Spiess PE; Agarwal N; Bangs R; Boorjian SA; Buyyounouski MK; Clark PE; Downs TM; Efstathiou JA; Flaig TW; Friedlander T; Greenberg RE; Guru KA; Hahn N; Herr HW; Hoimes C; Inman BA; Jimbo M; Kader AK; Lele SM; Meeks JJ; Michalski J; Montgomery JS; Pagliaro LC; Pal SK; Patterson A; Plimack ER; Pohar KS; Porter MP; Preston MA; Sexton WJ; Siefker-Radtke AO; Sonpavde G; Tward J; Wile G; Dwyer MA; Gurski LA
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1240-1267. PubMed ID: 28982750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020.
    Elkrief A; Joubert P; Florescu M; Tehfe M; Blais N; Routy B
    Curr Oncol; 2020 Feb; 27(1):52-60. PubMed ID: 32218661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of Metastatic Non-small Cell Lung Cancer].
    Reinmuth N; Gröschel A; Schumann C; Sebastian M; Wiewrodt R; Reck M
    Pneumologie; 2016 Sep; 70(9):567-78. PubMed ID: 27603945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    D'Addario G; Früh M; Reck M; Baumann P; Klepetko W; Felip E;
    Ann Oncol; 2010 May; 21 Suppl 5():v116-9. PubMed ID: 20555059
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
    Gkolfinopoulos S; Mountzios G
    Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
    [No Abstract]   [Full Text] [Related]  

  • 39. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
    Gentzler RD; Yentz SE; Johnson ML; Rademaker AW; Patel JD
    Cancer; 2014 Dec; 120(24):3853-8. PubMed ID: 25155290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New perspectives in the management of non-small-cell lung carcinoma (NSCLC)].
    Brockmöller J; Junker K; Multhoff G
    Onkologie; 2006 Sep; 29 Suppl 2():25-8. PubMed ID: 16974125
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.